Radiopharm Theranostics (RDPTF) EBT Growth (1y) (2024 - 2026)
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) EBT Growth (1y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.55 Bn | 197.56 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 181.17 Bn | 177.99 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 132.18 Bn | 124.33 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 61.66 Bn | 56.48 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 34.17 Bn | 30.86 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -82.20% |
| 9 | Roivant Sciences | 30.04 Bn | 30.04 Bn | 1.16 Mn | - |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | 98.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 98.14% |
| Jun 30, 2025 | 20.09% |
| Jun 30, 2024 | -38.41% |